RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis — Stella

Recruiting

Back to Sarcopenia in Elderly trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

The Chinese University of Hong Kong, Hong Kong

Key details

Phase

Post-approval study

Sponsor

Prince of Wales Hospital, Shatin, Hong Kong

Collaborators

Chinese University of Hong Kong

Enrollment target

~120 participants

Started

April 2024

Primary completion

April 2027

Age range

65 Years and older

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov